The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer

  title={The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer},
  author={Jos{\'e} Mª Mazarico Gallego and Mercedes Herrera Ju{\'a}rez and Luis Paz-Ares},
  journal={Expert Opinion on Drug Safety},
  pages={233 - 242}
ABSTRACT Introduction: Lung cancer is the leading cancer-related cause of death worldwide. The introduction of immune checkpoint inhibitors (ICIs) for the treatment of lung cancer has significantly improved the outcome of these patients. Pembrolizumab, a monoclonal IgG4-kappa antibody against programmed-death-1 (PD-1) protein, nowadays represents a standard of care for NSCLC patients. Although it has a favorable toxicity profile, some immune-related adverse events (irAEs) can be life… 
4 Citations
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
Ocular irAEs secondary to ICIs in lung cancer are non-negligible, particularly ophthalmoplegia, and Ethnicity and the type of ICIs play important roles in the distribution of ocularirAEs.
Research progress in immune checkpoint inhibitors for lung cancer in China
This review aims to summarize the recent advances and future directions of ICIs, including PD-1 inhibitors, PD-L1 inhibitor, cytotoxic T lymphocyte-associated antigen-4 inhibitors, bi-specific antibodies, and a novel inhibitor of T-cell immune-receptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains in immunotherapies for lung cancer in China.
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Ophthalmic immune-related adverse events are rare but could be more common than previously estimated and PD-L1-directed checkpoint inhibitors may have a slight predilection for ocular surface adverse effects.


Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
Pembrolizumab has acceptable safety in patients with cancer, HIV treated with ART, and a CD4+ T-cell count of greater than 100 cells/μL but may be associated with KSHV-associated B-cell lymphoproliferation but is appropriate for US Food and Drug Administration-approved indications and clinical trials in this population.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
  • R. Hui, E. Garon, N. Rizvi
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
Pembrolizumab provides promising long-term OS benefit with a manageable safety profile for PD-L1-expressing treatment-naive advanced NSCLC, with greatest efficacy observed in patients with TPS ≥50%.
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.